Company intelligence / Profile preview

Hemafund

Ukraine

Ownership: Private
Development stage: Other

Overview

Hemafund is the leading Ukrainian cord blood bank specializing in umbilical cord blood, placenta, umbilical cord tissue, and long-term cryostorage of human cells and tissues, recently partnering with Pluri to stockpile and distribute PLX-R18 cell therapy for radiation emergencies (in anticipation of clinical trials and regulatory registration)[1][2][3].

Therapeutic areas: Hematology
Modalities: Cell therapyStem cell therapyCryopreservation service
Industry: Non-Drug Biotech

Partnerships

Pluri (exclusive partnership to stockpile and potentially distribute PLX-R18 for radiation emergencies)[1][2]

Beyond the preview

Go deeper on Hemafund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemafund.

Explore the full profile